Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
NorLeu3-A in a formulation · 1 trial · 2 indications
| Arm | Type | Description |
|---|---|---|
| Placebo Vehicle Control | PLACEBO_COMPARATOR | control placebo vehicle gel |
| 0.03% DSC127 | ACTIVE_COMPARATOR | 0.03 % DSC127 in Vehicle Control |
| 0.01% DSC127 | ACTIVE_COMPARATOR | 0.01% DSC127 in Vehicle Control |
| Name | Type | Description |
|---|---|---|
| NorLeu3-A(1-7) in a gel formulation | DRUG | Gel will be applied to the wound once daily for four weeks (treatment period). Gel will have either no active ingredient (placebo), 0.03% or 0.01% active ingredient. |
Inclusion Criteria: * Have at least one chronic non-healing Wagner Grade 1 or Grade 2 plantar neuropathic diabetic ulcer between 1.0-6.0 cm2 on the midfoot or forefoot, including the toes but excluding the heel. * ABI greater than 0.7 for neuroischemic or greater than 0.8 for neuropathic DU * TcPO2...
NorLeu3-A in a formulation is being studied for the treatment of diabetic foot ulcers, a type of foot ulcer that occurs in people with diabetes. It is an investigational small molecule therapy currently in clinical development for this condition.
The specific molecular target of NorLeu3-A in a formulation has not been disclosed. It is a small molecule being investigated for its potential to treat diabetic foot ulcers, but its mechanism of action is not publicly detailed.
NorLeu3-A in a formulation is being developed by Integra LifeSciences Holdings Corporation, a company traded on the NASDAQ under the ticker symbol IART.
NorLeu3-A in a formulation is in Phase 2 clinical development. It is an investigational drug and has not been approved by regulatory authorities for the treatment of diabetic foot ulcers.
NorLeu3-A in a formulation has been studied in one completed Phase 2 clinical trial, identified as NCT00796744. This trial, titled 'Safety and Efficacy Study of DSC127 in Treating Subjects With Diabetic Ulcers,' enrolled 78 participants in the United States and was a randomized, double-blind, placebo-controlled study.
Yes, NorLeu3-A in a formulation is also known as DSC127. The clinical trial NCT00796744, which studied this drug for diabetic foot ulcers, refers to it as DSC127.